Literature DB >> 30779881

Loss of growth hormone-mediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity.

Yash Chhabra1,2, Caroline N Nelson2, Monika Plescher2,3, Johanna L Barclay2,4, Aaron G Smith5, Sof Andrikopoulos6, Salvatore Mangiafico6, David J Waxman7, Andrew J Brooks1,2, Michael J Waters2.   

Abstract

Growth hormone (GH) has an important function as an insulin antagonist with elevated insulin sensitivity evident in humans and mice lacking a functional GH receptor (GHR). We sought the molecular basis for this sensitivity by utilizing a panel of mice possessing specific deletions of GHR signaling pathways. Metabolic clamps and glucose homeostasis tests were undertaken in these obese adult C57BL/6 male mice, which indicated impaired hepatic gluconeogenesis. Insulin sensitivity and glucose disappearance rate were enhanced in muscle and adipose of mice lacking the ability to activate the signal transducer and activator of transcription (STAT)5 via the GHR (Ghr-391-/-) as for GHR-null (GHR-/-) mice. These changes were associated with a striking inhibition of hepatic glucose output associated with altered glycogen metabolism and elevated hepatic glycogen content during unfed state. The enhanced hepatic insulin sensitivity was associated with increased insulin receptor β and insulin receptor substrate 1 activation along with activated downstream protein kinase B signaling cascades. Although phosphoenolpyruvate carboxykinase (Pck)-1 expression was unchanged, its inhibitory acetylation was elevated because of decreased sirtuin-2 expression, thereby promoting loss of PCK1. Loss of STAT5 signaling to defined chromatin immunoprecipitation targets would further increase lipogenesis, supporting hepatosteatosis while lowering glucose output. Finally, up-regulation of IL-15 expression in muscle, with increased secretion of adiponectin and fibroblast growth factor 1 from adipose tissue, is expected to promote insulin sensitivity.-Chhabra, Y., Nelson, C. N., Plescher, M., Barclay, J. L., Smith, A. G., Andrikopoulos, S., Mangiafico, S., Waxman, D. J., Brooks, A. J., Waters, M. J. Loss of growth hormone-mediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity.

Entities:  

Keywords:  gluconeogenesis; hepatic glucose output; metabolism

Year:  2019        PMID: 30779881      PMCID: PMC6463913          DOI: 10.1096/fj.201802328R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  77 in total

1.  Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.

Authors:  Cullen M Taniguchi; Thien T Tran; Tatsuya Kondo; Ji Luo; Kohjiro Ueki; Lewis C Cantley; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

2.  A primary defect in glucose production alone cannot induce glucose intolerance without defects in insulin secretion.

Authors:  Salvatore P Mangiafico; Shueh H Lim; Sandra Neoh; Helene Massinet; Christos N Joannides; Joseph Proietto; Sofianos Andrikopoulos; Barbara C Fam
Journal:  J Endocrinol       Date:  2011-06-23       Impact factor: 4.286

3.  A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse).

Authors:  Y Zhou; B C Xu; H G Maheshwari; L He; M Reed; M Lozykowski; S Okada; L Cataldo; K Coschigamo; T E Wagner; G Baumann; J J Kopchick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in growth hormone treated animals.

Authors:  Raphael R Prattali; Guilherme C Barreiro; Caio T Caliseo; Felipe Y Fugiwara; Mirian Ueno; Patrícia O Prada; Licio A Velloso; Mario J A Saad; José B C Carvalheira
Journal:  FEBS Lett       Date:  2005-06-06       Impact factor: 4.124

5.  Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.

Authors:  W S Cutfield; P Wilton; H Bennmarker; K Albertsson-Wikland; P Chatelain; M B Ranke; D A Price
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

6.  Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5.

Authors:  Paul W Caton; Nanda K Nayuni; Julius Kieswich; Noorafza Q Khan; Muhammed M Yaqoob; Roger Corder
Journal:  J Endocrinol       Date:  2010-01-21       Impact factor: 4.286

7.  Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected].

Authors:  Bangyan Stiles; Ying Wang; Andreas Stahl; Sara Bassilian; W Paul Lee; Yoon-Jung Kim; Robert Sherwin; Sherin Devaskar; Ralf Lesche; Mark A Magnuson; Hong Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

8.  The STAT5A-mediated induction of pyruvate dehydrogenase kinase 4 expression by prolactin or growth hormone in adipocytes.

Authors:  Ursula A White; Ann A Coulter; Tiffany K Miles; Jacqueline M Stephens
Journal:  Diabetes       Date:  2007-03-14       Impact factor: 9.461

9.  Metformin inhibits growth hormone-mediated hepatic PDK4 gene expression through induction of orphan nuclear receptor small heterodimer partner.

Authors:  Yong Deuk Kim; Yong-Hoon Kim; Surendar Tadi; Ji Hoon Yu; Yong-Hyeon Yim; Nam Ho Jeoung; Minho Shong; Lothar Hennighausen; Robert A Harris; In-Kyu Lee; Chul-Ho Lee; Hueng-Sik Choi
Journal:  Diabetes       Date:  2012-06-14       Impact factor: 9.461

10.  Disruption of JAK2 in adipocytes impairs lipolysis and improves fatty liver in mice with elevated GH.

Authors:  Sarah M Nordstrom; Jennifer L Tran; Brandon C Sos; Kay-Uwe Wagner; Ethan J Weiss
Journal:  Mol Endocrinol       Date:  2013-06-19
View more
  9 in total

Review 1.  Metabolic Messengers: fibroblast growth factor 1.

Authors:  Emanuel Gasser; Gencer Sancar; Michael Downes; Ronald M Evans
Journal:  Nat Metab       Date:  2022-06-09

Review 2.  Growth Hormone Receptor Regulation in Cancer and Chronic Diseases.

Authors:  Ger J Strous; Ana Da Silva Almeida; Joyce Putters; Julia Schantl; Magdalena Sedek; Johan A Slotman; Tobias Nespital; Gerco C Hassink; Jan A Mol
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-18       Impact factor: 5.555

3.  Growth Hormone Upregulates Mediators of Melanoma Drug Efflux and Epithelial-to-Mesenchymal Transition In Vitro and In Vivo.

Authors:  Yanrong Qian; Reetobrata Basu; Samuel C Mathes; Nathan A Arnett; Silvana Duran-Ortiz; Kevin R Funk; Alison L Brittain; Prateek Kulkarni; Joseph C Terry; Emily Davis; Jordyn T Singerman; Brooke E Henry; Edward O List; Darlene E Berryman; John J Kopchick
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

Review 4.  Towards Understanding the Direct and Indirect Actions of Growth Hormone in Controlling Hepatocyte Carbohydrate and Lipid Metabolism.

Authors:  Mari C Vázquez-Borrego; Mercedes Del Rio-Moreno; Rhonda D Kineman
Journal:  Cells       Date:  2021-09-24       Impact factor: 6.600

5.  IL-15 Participates in the Pathogenesis of Polycystic Ovary Syndrome by Affecting the Activity of Granulosa Cells.

Authors:  Yan Liu; Zhi Li; Yang Wang; Qingqing Cai; Haiou Liu; Congjian Xu; Feifei Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-18       Impact factor: 5.555

Review 6.  Classical and novel GH receptor signaling pathways.

Authors:  Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2020-08-22       Impact factor: 4.102

Review 7.  Dual Characters of GH-IGF1 Signaling Pathways in Radiotherapy and Post-radiotherapy Repair of Cancers.

Authors:  Yunyun Cheng; Wanqiao Li; Ruirui Gui; Chunli Wang; Jie Song; Zhaoguo Wang; Xue Wang; Yannan Shen; Zhicheng Wang; Linlin Hao
Journal:  Front Cell Dev Biol       Date:  2021-06-09

8.  Dynamics of Chinese Diet Divergence from Chinese Food Pagoda and Its Association with Adiposity and Influential Factors: 2004-2011.

Authors:  Jiajun Zhou; Sirimaporn Leepromrath; Xu Tian
Journal:  Int J Environ Res Public Health       Date:  2020-01-13       Impact factor: 3.390

9.  Growth hormone receptor promotes breast cancer progression via the BRAF/MEK/ERK signaling pathway.

Authors:  Xiaojue Zhu; Yonghao Li; Guoxin Xu; ChangQing Fu
Journal:  FEBS Open Bio       Date:  2020-05-06       Impact factor: 2.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.